home.social

#biopharma — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #biopharma, aggregated by home.social.

  1. NEW: Anthropic buried the lede in its Claude Science event today: It's going to start developing its own drugs.

    Details are scarce, but @matthewherper and I talked to Anthropic executives to bring you some exclusive tidbits about the program:

    statnews.com/2026/06/30/anthro

    #health #healthcare #medicine #biotech #pharma #biopharma #drugdevelopment #AI #artificialintelligence #claude #anthropic

  2. 𝗜𝘀 𝗔𝗣𝗔𝗖 𝗯𝗲𝗰𝗼𝗺𝗶𝗻𝗴 𝗮 $𝟰𝟰 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗽𝗼𝘄𝗲𝗿𝗵𝗼𝘂𝘀𝗲?
    The market is 𝘃𝗮𝗹𝘂𝗲𝗱 𝗮𝘁 ~𝗨𝗦𝗗 𝟰𝟰 𝗯𝗶𝗹𝗹𝗶𝗼𝗻, driven by rising demand for 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀, 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀, 𝗮𝗻𝗱 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 across healthcare systems.
    𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: kenresearch.com/industry-repor

    #Biopharma #APACHealthcare #Biologics #PharmaGrowth

  3. Merck claims late-stage study success for RSV antibody  — Novo Nordisk's Wegovy gets UK approval for lowering heart risks — J&J vets burst into biotech with $165M Third Arc series A —bit.ly/w28kSd #rsv #merck #novonordisk #uk #wegovy #funding #jnj #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  4. Abbott plans marketing push for glucose monitors beyond diabetes  — Morphic kept it simple in M&A maneuvers, staying focused on Lilly to reel in $3.2B buyout— FDA launches innovation hub to spur rare disease R&D —bit.ly/w28kSd #cgms #glucosemonitoring #abbottlabs #elililly #innovation #fda #rarediseases #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  5. 5 neuro data readouts to watch in the second half of 2024 — GSK moves to new HQ in return to central London — AbbVie led the way in paying doctors to pitch its drugs last year —bit.ly/w28kSd #clinicaltrials #neurology #gsk #london #abbvie #physicians #physicianpayments #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  6. Pfizer moves forward with once-daily version of weight loss pill after setbacks—Novo’s once-weekly insulin rejected by FDA — Could pharma’s blockbuster immunotherapies work in dogs? —bit.ly/w28kSd #pfizer #weightloss #novonordisk #type1diabetes #fda #insulin #animalhealth #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  7. 2024's layoff woes continue in Q2—Jaguar Gene’s JAG201 therapy trial for autism receives FDA approval — Most patients stop using Wegovy, Ozempic for weight loss within two years —bit.ly/w28kSd #layoffs #genetherapy #autism #wegovy #ozempic #weightloss #novonordisk #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  8. US government appeals Gilead's trial win in Truvada, Descovy patent fight—Lilly’s Mounjaro helps patients lose more weight than Novo’s Ozempic — FTC report finds PBM power has “dire consequences” —bit.ly/w28kSd #gileadsciences #patents #elililly #mounjaro #ozempic #novonordisk #ftc #pbms #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  9. Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster—GLP-1s may cut risk of 10 obesity-related cancers in diabetics —Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births —bit.ly/w28kSd #mergersandacquistions #elililly #ibd #takeda #glp1 #novonordisk #diabetes #cancer #pfizer #rsv #vaccines #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  10. Moderna receives $176 million from BARDA for mRNA influenza vaccines—J&J, Legend's Carvykti shows CAR-T can extend lives in multiple myeloma —The IRA will lower U.S. drug spending, CMS finds — but not for awhile—bit.ly/w28kSd #moderna #barda #mrna #vaccines #flu #jnj #multiplemyeloma #ira #drugspending #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  11. Gilead’s Trodelvy stumbles in late-stage trials but remains prized cancer asset—BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival —Supreme Court’s Chevron Doctrine ruling could limit FDA’s regulatory authority—bit.ly/w28kSd #gileadsciences #cancer #antibodydrugconjufate #eisai #bristolmyerssquibb #supremecourt #fda #chevrondoctrine #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  12. ​​​​​​​Alumis cuts IPO size, but nets $250M for immune drug work—Philips BiPAP recall now linked to 65 deaths, 952 injuries —Where the future of Alzheimer's drugs is heading—bit.ly/w28kSd #ipos #recalls #medtech #bipap #philips #alzheimers #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  13. Supreme Court rejects controversial Purdue Pharma bankruptcy deal—FDA approves Verona Pharma's inhaled COPD therapy —FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug—bit.ly/w28kSd #supremecourt #purduepharma #bankruptcy #opioidcrisis #fda #copd #merck #cancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  14. After full approval, Sarepta lays out its next moves—Zealand Pharma brings in $1B to drive development of obesity drugs —Sanofi seeks initial offers for Its $20 billion consumer arm—bit.ly/w28kSd #sareptatherapeutics #dmd #obesity #zealandpharma #funding #consumerhealth #sanofi #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  15. 5 FDA decisions to watch in the second half of 2024—Lilly sees path for Zepbound’s label expansion with phase III sleep apnea win —BMS gets FDA approval for Krazati in colorectal cancer—bit.ly/w28kSd #fda #elililly #sleepapnea #bristolmyerssquibb #colorectalcancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  16. Chronic kidney disease market estimated to grow at 19.6%, driven by pipeline agents aimed at unmet needs—Lexicon Pharmaceuticals resubmits sotagliflozin NDA for type 1 diabetes —Former Stimwave CEO gets 6 years in prison for fake device scheme—bit.ly/w28kSd #chronickidneydisease #kidneydisease #medtech #type1diabetes #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  17. Biopharma dealmaking continues to rise, but M&A values hold steady—Vanda rejects buyout offers, pans 'opportunistic attempts' at securing its shares at a discount —Lilly files more lawsuits to curb sales of counterfeit Mounjaro—bit.ly/w28kSd #mergersandacquisitions #vandapharma #elililly #counterfeitdrugs #mounjaro #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  18. AstraZeneca’s Truqap flops in phase III triple-negative breast cancer trial—Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval —Roche partners with RNA editing biotech Ascidian—bit.ly/w28kSd #astrazeneca #breastcancer #clinicaltrials #endometrialcancer #merck #fda #rna #roche #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  19. GLP-1 global obesity market to reach $111B by 2033, despite headwinds—Takeda circles leukemia rival to Novartis' Scemblix in up to $1.3B deal with Ascentage —J.P. Morgan's private financing arm closes inaugural $500M-plus biotech fund—bit.ly/w28kSd #obesity #glp1 #novonordisk #elililly #novartis #takeda #vml #funding #jpmorgan #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  20. Coherus, Junshi’s PD-1 blocker Loqtorzi aces phase III liver cancer trial—Supreme Court preserves access to abortion pill mifepristone —Pfizer gene therapy for Duchenne fails to meet goals of key trial—bit.ly/w28kSd #surpremecourt #livercancer #pfizer #dmd #genetherapy #abortionpill #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  21. The 6 largest biopharma layoffs of 2024 so far—Biosecure Act left out of Department of Defense spending bill by House Rules Committee —Pfizer, Flagship name first target for multibillion-dollar collaboration: obesity—bit.ly/w28kSd #layoffs #biosecureact #legislation #pfizer #obesity #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  22. After M&A stretch, Pfizer CEO says company needs 'breathing period' from large deals—Behind Big Pharma’s layoffs — is there an end in sight? — Lilly Alzheimer’s drug gets unanimous backing of FDA panel—bit.ly/w28kSd #pfizer #bigpharma #layoffs #alzheimers #elililly #fda #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma